167 related articles for article (PubMed ID: 34729154)
1. A modified regimen of low-dose rituximab therapy for patients with refractory immune thrombocytopenia associated with systemic lupus erythematosus.
Zhang S; Jiang N; Wang L; Zhang L; Chen H; Li M; Zeng X
Ther Adv Chronic Dis; 2021; 12():20406223211048643. PubMed ID: 34729154
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
Jiang B; Li T; Guo L; Shen H; Ye S; Chen S
J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
[TBL] [Abstract][Full Text] [Related]
3. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus.
Ilizaliturri-Guerra O; Uriarte-Botello R; Pineda-Sic RÁ; Serna-Peña G; Garza-Elizondo MA; Galarza-Delgado DÁ; Leal-Bramasco AS; Elizondo-Solís CV; Santoyo-Fexas L; Villarreal-Alarcón MÁ
Rheumatol Int; 2020 Oct; 40(10):1717-1724. PubMed ID: 32797277
[TBL] [Abstract][Full Text] [Related]
4. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study.
Chen H; Zheng W; Su J; Xu D; Wang Q; Leng X; Zhang W; Li M; Tang F; Zhang X; Zeng X; Zhao Y; Zhang F
Rheumatology (Oxford); 2011 Sep; 50(9):1640-4. PubMed ID: 21571767
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.
Iaccarino L; Bartoloni E; Carli L; Ceccarelli F; Conti F; De Vita S; Ferraccioli G; Galeazzi M; Gatto M; Gerli R; Govoni M; Gremese E; Iuliano A; Mansutti E; Moroni G; Mosca M; Nalli C; Naretto C; Padovan M; Palma L; Raffiotta F; Roccatello D; Tincani A; Valesini G; Zen M; Doria A
Clin Exp Rheumatol; 2015; 33(4):449-56. PubMed ID: 26053285
[TBL] [Abstract][Full Text] [Related]
6. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
7. Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study.
Sun F; Chen J; Wu W; Geng S; Xu W; Sun S; Chen Z; Gu L; Wang X; Li T; Ye S
Clin Rheumatol; 2020 Oct; 39(10):3099-3104. PubMed ID: 32418039
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
[TBL] [Abstract][Full Text] [Related]
9. Rituximab alleviates pediatric systemic lupus erythematosus associated refractory immune thrombocytopenia: a case-based review.
Mu F; Bai X; Lou Y; Luo P; Guo Q
Immunol Res; 2024 Jan; ():. PubMed ID: 38279058
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of a patient with refractory immune thrombocytopenic purpura in systemic lupus erythematosus with rituximab.
Abe K; Ishikawa Y; Ishikawa J; Fujiwara M; Kita Y
Immunol Med; 2019 Dec; 42(4):185-188. PubMed ID: 31794352
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.
Trachana M; Koutsonikoli A; Farmaki E; Printza N; Tzimouli V; Papachristou F
Rheumatol Int; 2013 Mar; 33(3):809-13. PubMed ID: 22101555
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab.
Ma W; Bai W; Wu X; Zhao J; Li M; Zeng X
Lupus; 2020 Dec; 29(14):1961-1967. PubMed ID: 32838618
[TBL] [Abstract][Full Text] [Related]
14. Treatment of refractory lupus nephritis using leflunomide: A prospective study.
Zhang S; Chen Y; Chen X; Zhao Y; Zeng X; Zhang F; Wang L; Li M
Front Immunol; 2023; 14():1133183. PubMed ID: 37006280
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.
Hogan J; Godron A; Baudouin V; Kwon T; Harambat J; Deschênes G; Niel O
Pediatr Nephrol; 2018 Jan; 33(1):111-116. PubMed ID: 28780657
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of laparoscopic splenectomy in thrombocytopenia secondary to systemic lupus erythematosus.
Zhou J; Wu Z; Zhou Z; Wang Z; Liu Y; Huang XY; Peng B
Clin Rheumatol; 2013 Aug; 32(8):1131-8. PubMed ID: 23549638
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of rituximab therapy in refractory lupus: A meta-analysis.
Alshaiki F; Obaid E; Almuallim A; Taha R; El-Haddad H; Almoallim H
Eur J Rheumatol; 2018 Jul; 5(2):118-126. PubMed ID: 30185361
[TBL] [Abstract][Full Text] [Related]
18. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
19. Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus.
Bang SY; Lee CK; Kang YM; Kim HA; Suh CH; Chung WT; Park YB; Choe JY; Kim TJ; Park YW; Yoo DH; Bae SC; Lee HS
Autoimmune Dis; 2012; 2012():565039. PubMed ID: 23304457
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.
Tanaka Y; Yamamoto K; Takeuchi T; Nishimoto N; Miyasaka N; Sumida T; Shima Y; Takada K; Matsumoto I; Saito K; Koike T
Mod Rheumatol; 2007; 17(3):191-7. PubMed ID: 17564773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
